TRAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
First Tracks Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$36.28+1.82 (+5.28%)
Close on Oct 19, 2026
- Market cap
- $1.27B
- P/E (TTM)
- –
- Dividend yield
- –
About First Tracks Biotherapeutics
Pharmaceutical Preparations, SIC 2834
First Tracks Biotherapeutics, Inc. is listed on Nasdaq under the ticker TRAX, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- First Tracks Biotherapeutics, Inc.
- Headquarters
- San Diego, CA
- Address
- 10770 Wateridge Circle, Suite 210 92121
- Phone
- (212) 373-3000
- Website
- firsttracksbio.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- TRAX
- Exchange
- Nasdaq
- IPO date
- Apr 6, 2026
- Shares outstanding
- 36M, Aug 7, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 2091349
- CUSIP
- 337185102
- ISIN
- US3371851029
- LEI
- 529900CGIGKN4R5RO925
- EIN
- 39-5003207
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Daniel Faga | President, CEO, Director | 496,684 |
| Paul F. Lizzul | Chief Medical Officer | 42,669 |
| Benjamin Stone | Chief Business Officer | 17,262 |
| Ajim Tamboli | Chief Financial Officer | – |
| John A. Orwin | Director | 17,995 |
| J. Anthony Ware | Director | 15,660 |
| Rita Jain | Director | 19,194 |
| John P. Schmid | Director | 37,652 |
| Dennis M. Fenton | Director | 10,995 |
| Magda Marquet | Director | 15,960 |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 20, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 3, 2026 | Spin-off | Registration as a new public company (Form 10), e.g. spin-off |
| Feb 6, 2026 | Name change | Name changed from Biopharma Company, Inc. to First Tracks Biotherapeutics, Inc. |